Abstract

Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≤1 year, *P

Original languageEnglish
Pages (from-to)539-553
Number of pages15
JournalBreast Cancer Research and Treatment
Volume121
Issue number3
DOIs
Publication statusPublished - Jun 2010

Keywords

  • Breast cancer
  • Enolase-1
  • Estrogen receptor alpha
  • Nuclear factor kappa B
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells'. Together they form a unique fingerprint.

  • Cite this